It is suggested for use in combination with chemotherapy for the treatment of HER2 overexpressing breast cancer.586 In the phase III TRIO-013/LOGiC trial, lapatinib was tested in combination with chemotherapy in HER2-positive gastric and esophageal cancer. Here, ERBB2 is linked to breast carcinoma.